Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 148

1.

Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women.

Lambrinoudaki I, Vlachou S, Galapi F, Papadimitriou D, Papadias K.

Clin Interv Aging. 2008;3(3):445-51. Review.

2.

Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.

Woodis CB.

Ann Pharmacother. 2008 Jul;42(7):1085-9. doi: 10.1345/aph.1K652.

PMID:
18505912
3.

[Fracture prevention in postmenopausal women with osteoporosis by an annual infusion of zoledronic acid].

Geusens PP, Lems WF.

Ned Tijdschr Geneeskd. 2007 Jun 30;151(26):1445-8. Dutch.

PMID:
17633971
4.

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR; HORIZON Pivotal Fracture Trial..

N Engl J Med. 2007 May 3;356(18):1809-22.

5.

A once-yearly IV bisphosphonate for osteoporosis.

[No authors listed]

Med Lett Drugs Ther. 2007 Nov 5;49(1273):89-90. No abstract available.

PMID:
17975523
6.

Intravenous zoledronic acid in postmenopausal women with low bone mineral density.

Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Jaeger P, Body JJ, Brandi ML, Broell J, Di Micco R, Genazzani AR, Felsenberg D, Happ J, Hooper MJ, Ittner J, Leb G, Mallmin H, Murray T, Ortolani S, Rubinacci A, Saaf M, Samsioe G, Verbruggen L, Meunier PJ.

N Engl J Med. 2002 Feb 28;346(9):653-61.

7.

Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.

Roux C, Reid DM, Devogelaer JP, Saag K, Lau CS, Reginster JY, Papanastasiou P, Bucci-Rechtweg C, Su G, Sambrook PN.

Osteoporos Int. 2012 Mar;23(3):1083-90. doi: 10.1007/s00198-011-1800-1.

PMID:
21975559
8.

Yearly zoledronic acid in postmenopausal osteoporosis.

de Nijs RN, Westgeest AA.

N Engl J Med. 2007 Aug 16;357(7):711; author reply 714-5. No abstract available.

9.

Annual zoledronic acid for osteoporosis.

BMJ Group..

Drug Ther Bull. 2008 Dec;46(12):93-6. Review.

PMID:
19056701
10.

Zoledronic acid: a review of its use in the treatment of osteoporosis.

Deeks ED, Perry CM.

Drugs Aging. 2008;25(11):963-86. doi: 10.2165/0002512-200825110-00007. Review.

PMID:
18947264
11.

The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis.

Hwang JS, Chin LS, Chen JF, Yang TS, Chen PQ, Tsai KS, Leung PC.

J Bone Miner Metab. 2011 May;29(3):328-33. doi: 10.1007/s00774-010-0223-y.

PMID:
20922438
12.

Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.

Cosman F, Eriksen EF, Recknor C, Miller PD, GuaƱabens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S.

J Bone Miner Res. 2011 Mar;26(3):503-11. doi: 10.1002/jbmr.238.

13.

[Evidences of safety and tolerability of the zoledronic acid 5 mg yearly in the post-menopausal osteoporosis: the HORIZON project].

Dalle Carbonare L, Bertoldo F, Lo Cascio V.

Reumatismo. 2009 Jan-Mar;61(1):54-64. Italian.

14.

Yearly zoledronic acid in postmenopausal osteoporosis.

Najib MA, Aziz I.

N Engl J Med. 2007 Aug 16;357(7):713; author reply 714-5. No abstract available.

PMID:
17703527
15.

Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice.

Sieber P, Lardelli P, Kraenzlin CA, Kraenzlin ME, Meier C.

Clin Drug Investig. 2013 Feb;33(2):117-22. doi: 10.1007/s40261-012-0041-1.

PMID:
23184667
16.

Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.

McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.

Bone. 2007 Jul;41(1):122-8.

PMID:
17468062
17.

A review of minodronic acid hydrate for the treatment of osteoporosis.

Tanishima S, Morio Y.

Clin Interv Aging. 2013;8:185-9. doi: 10.2147/CIA.S23927. Review.

18.

Yearly zoledronic acid in postmenopausal osteoporosis.

Chang JT.

N Engl J Med. 2007 Aug 16;357(7):713-4; author reply 714-5. No abstract available.

PMID:
17703528
19.

Effect of single dose intravenous zoledronic acid on bone mineral density in post-menopausal osteoporosis of Bangladeshi women.

Hossain M, Chowdhury IH, Emran MA, Habib AH, Asaduzzamnan AK, Alam M, Ferdous C.

Bangladesh Med Res Counc Bull. 2010 Dec;36(3):74-7.

PMID:
21548542
20.

Single annual injectable treatment for postmenopausal osteoporosis.

Chapurlat RD.

Expert Opin Drug Deliv. 2008 May;5(5):583-91. doi: 10.1517/17425247.5.5.583 . Review.

PMID:
18491983
Items per page

Supplemental Content

Support Center